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CRITICAL VALUES FOR AUTOMATED BLOOD COUNTS AND
PERIPHERAL BLOOD SLIDES
VALORES CRÍTICOS PARA HEMOGRAMAS AUTOMATIZADOS Y FROTIS DE SANGRE PERIFÉRICA
Huerto JL 1,a, Villaorduña AM 1,a

ABSTRACT
Objective: The reporting of critical values is considered a necessary practice in clinical pathology laboratories
since immediate communication determines therapeutic decisions that can save lives. The choice of critical
values and the way they are reported must be a joint decision between laboratory specialists and clinical
professionals from each health facility since they must be integrated into the dynamics of the services involved.
Among the critical values that have been chosen for this review, we have included quantitative parameters,
whose processing is carried out in automated hematology analyzers, and morphological ndings in peripheral
blood smears, which trained professionals evaluate.

Keywords: Pathology; Blood; Cytology; Laboratories; Microscopy. (Source: MESH-NLM)

RESUMEN
Objetivo: El reporte de valores críticos se considera una práctica necesaria en los laboratorios de patología
clínica, pues su comunicación inmediata determina decisiones terapéuticas que pueden salvar vidas. La
elección de los valores críticos y el modo en que son reportados debe ser una decisión conjunta entre los
especialistas del laboratorio y los profesionales clínicos de cada establecimiento de salud, ya que deben
integrarse a la dinámica de los servicios involucrados. Entre los valores críticos que se han escogido para esta
revisión hemos incluido parámetros cuantitativos, cuyo procesamiento se ejecuta en analizadores
hematológicos automatizados, y hallazgos morfológicos en los frotis de sangre periférica, lo cuales son
evaluados por profesionales capacitados.

Palabras clave: Patología; Sangre; Citología; Laboratorios; Microscopía. (Fuente: DeCS- BIREME)
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INTRODUCTION
Critical values in clinical pathology are de ned as results
that re ect imminent threats to patients' lives unless
therapeutic measures are administered promptly (1).
These results are often far outside the upper or lower
limits of the “normal” ranges. Therefore, one should not
fall into the error of considering "critical" any result that
exceeds the reference values, that is, the expected
values in healthy individuals (1). The crucial diﬀerence
between a critical and abnormal value is that, in the rst
case, the result indicates an urgent danger to the
patient's life.
Likewise, a clear distinction must be made between
critical and vital values. The latter are “values that
represent a pathophysiological state so diﬀerent from
normal as to be life-threatening and for which
corrective measures can be taken, but for which prompt
action is not so crucial (2). ” As we can see, a vital value is as
important as a critical value, but the immediacy of its
report is not so decisive.
Currently, clinical laboratories are responsible for
determining and communicating their critical values,
de ned according to the complexity of each service, the
type of users it serves, the resources available, and the
local epidemiological pro le. The eﬀective practice of
reporting critical values implies a decrease in mortality
and morbidity in health systems and a reduction in costs
derived from preventable complications and damages
(3)
.
In hematology laboratories, there is a lack of consensus
about which results should be considered critical, as
well as discrepancies in terminology and reporting
mechanisms (4). Although selecting critical values is the
responsibility of each clinical pathology service, we
consider it pertinent to propose a list of results
(explaining, for each one, the reasons that justify their
selection) that serves as a starting point for other
laboratories to de ne or re ne their results. own critical
value reporting processes.
CRITICAL VALUES FOR AUTOMATED BLOOD CELL
COUNTS
Hemoglobin less than 7 g/dL
The mortality of postoperative patients who refused
packed red cell transfusions for religious reasons has
been investigated.
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These studies have concluded that hemoglobin levels
between 7 g/dL and 8 g/dL are associated with a low risk
of mortality, while levels below 6 g/dL are associated
with extremely high levels of mortality (5-7). Bleeding
(38.5%), respiratory failure (35.9%), kidney failure
(28.2%), sepsis (20.5%), and cardiac infarction (12.8%)
were the main causes of death for these patients (6).
Likewise, the AABB's most recent clinical practice
guideline (American Association of Blood Banks)
recommends a hemoglobin threshold of 7 g/dL to
indicate transfusion of packed red blood cells in
hemodynamically stable patients (8).
Hemoglobin greater than 22 g/dL and hematocrit
greater than 65% in neonates
A hematocrit greater than 65% or a hemoglobin level
greater than 22 g/dL de ne neonatal polycythemia: an
abnormal elevation in the mass of circulating
erythrocytes that generates hyperviscosity blood (9-11).
Hyperviscosity in neonates is associated with decreased
blood supply to organs such as the brain, heart, lungs,
and intestine. The resulting hypoperfusion can lead to
life-threatening conditions such as systemic hypoxia,
hypoglycemia, necrotizing enterocolitis, seizures, and
other neurological symptoms (10). Although the optimal
management for neonates with polycythemia has not
been standardized, exchange transfusion is usually
indicated; however, this decision remains controversial
(10-11)
.
Hematocrit greater than 65%
inheart patients In patients with cyanotic congenital
heart disease, the main hematological complication
consists of an increase in hematocrit and hemoglobin
concentration. These changes are secondary to the
production of erythropoietin in the kidneys, which, in
turn, is induced by hypoxemia (12). Erythropoietin
stimulates the production of red blood cells in the bone
marrow, causing erythrocytosis in peripheral blood.
This increase in the amount of circulating erythrocytes
produces an increase in blood viscosity, which can
condition stasis and blockage of the capillaries.
Symptoms of hyperviscosity usually appear when the
hematocrit exceeds a value of 65% and are especially
related to a progressive increase in hematocrit (13).
Hyper viscosity syndrome, characterized by
neurological and cardiopulmonary symptoms, can give
rise to life-threatening complications, such as cardiac
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infarction, thromboembolic events, and ischemia in
multiple organs (14).

neutropenia has been estimated at 9.5%, although the
percentages are signi cantly higher in patients with
major comorbidities, fungal infections, and sepsis (26).

Le u ko c y te co u nt g re ate r t h a n 1 0 0 , 0 0 0 / u L
Hyperleukocytosis
is de ned as a leukocyte count greater than 100,000/uL
(15-16)
. This condition, in hematological pathologies such
as acute myeloid leukemia and acute lymphoblastic
leukemia, can produce a leukostasis syndrome.
Leukostasis syndrome is characterized by neurological
and cardiopulmonary symptoms and is considered a
hemato-oncological emergency. In patients with acute
myeloid leukemia, particularly, leukostasis is associated
with a poor prognosis due to a high risk of early
mortality and a high probability of long-term
recurrence and death (16). Rapid cytoreduction by
leukapheresis has been proposed as a therapeutic
action in patients with leukostasis due to acute
leukemia; this measure has been shown to reduce early
mortality in patients with leukostasis (17-18).
Leukocyte count greater than 50,000/uL and a
neutrophil count greater than 30,000/uL in
neonates
A persistent leukocytosis greater than 50,000/uL not
associated with leukemia is called leukemoid reaction,
its main causes being infections, intoxications, tumors
solids, severe bleeding and hemolysis (19-20). In neonates,
the leukemoid reaction is de ned by a white blood cell
count greater than 50,000/uL or a neutrophil count
greater than 30,000/uL and, in low birth weight patients,
is associated with life-threatening conditions such as
neonatal sepsis, intraventricular hemorrhage and
bronchopulmonary dysplasia (21). Mortality due to
neonatal sepsis has been estimated between 11% and
19% (22), and increases signi cantly in the case of
multidrug-resistant microorganisms (23) . Likewise, in our
environment, mortality due to intraventricular
hemorrhage in low birth-weight neonates has been
estimated at 47.1% (24) .
Neutrophil count less than 500/uL
Febrile neutropenia, a condition de ned by a neutrophil
count less than 500/uL in the presence of fever
(temperature greater than 38°C on two consecutive
readings), is a signi cant cause of morbidity and
mortality in cancer patients (25). In adult cancer patients,
in-hospital mortality associated
with
febrile

Likewise, in adult patients receiving myelosuppressive
chemotherapy, febrile neutropenia is associated with a
15% higher mortality than in patients without febrile
neutropenia (27), since it predisposes a severe infection by
fungi, gram-negative bacilli, and gram-positive cocci (28).
In pediatric patients receiving myelosuppressive
chemotherapy, febrile neutropenia is de ned by a
neutrophil count of less than 500 u/L or less than
1000/uL with a predicted decline over the next two days
(29)

.In this group of patients, in-hospital mortality

associated with febrile neutropenia is estimated at 5%
for gram-positive infections, 18% for gram-negative
infections, and higher percentages for fungal infections
(30)

.

Platelet count less than 10,000/uL
Thrombocytopenia is de ned as a platelet count of less
than 150,000/uL (31-32). Patients with platelets above
50,000/uL often have no symptoms or clinical ndings;
bleeding from minimal trauma or prolonged bleeding
from wounds usually appears with values below
30,000/uL and spontaneous bleeding events,
considered a hematological emergency, occur with
values below 10,000/uL (31-32).
Platelet count greater than 1,000,000/uL
A platelet value greater than 1,000,000/uL is associated
with acquired von Willebrand syndrome: de ciency of
von Willebrand factor multimers caused by increased
proteolytic activity of ADAMTS13 (33). The risk of bleeding
is therefore increased in these extreme
thrombocytoses. In patients with essential
thrombocythemia, a platelet value greater than
1,000,000/uL, associated with a history of minor
bleeding and a disease time greater than 15 years, is
considered a high-risk factor for hemorrhage (34) .
Likewise, it is recommended to moderate or restrict the
use of aspirin in patients with essential
thrombocythemia who reach platelet levels above
1,000,000/uL (33-34).
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Table 1. Critical values for automated blood counts.
PARAMETER
Hemoglobin

CRITICAL VALUES FOR AUTOMATED BLOOD COUNTS
VALUES / FINDINGS
INTERPRETATION
< 7 g/dL

Risk of death in post-surgery.
Recommended transfusion, with exceptions.

> 22 g/dL

Neonates: De nition of polycythemia.
Risk of hyperviscosity.

Hematocrit

> 65%

Hyperviscosity symptoms in heart patients.
A possible indication of bleeding.
Neonates: De nition of polycythemia.
Exponential risk of hyperviscosity in neonatal
polycythemia. Possible indication for exchange
transfusion.

Leukocytes

> 100 000/uL

Risk of death due to leukostasis.

> 50 000/uL (neonatos)

Possible indication for leukapheresis.
Risk of death in neonatal leukemoid reaction.

Neutrophils

Platelets

< 500/uL

Risk of death associated with febrile neutropenia.

> 30 000/uL (neonatos)

Risk of death in neonatal leukemoid reaction.

< 10 000/uL

Risk of death from spontaneous bleeding.

> 1 000 000/uL

Acquired von Willebrand factor de ciency,
risk of bleeding, and aspirin contraindication.

CRITICAL VALUES FOR PERIPHERAL BLOOD
Smears
Schistocytes
The International Council for Standardization in
Haematology (ICSH), which we can translate as the
International Committee for Standardization in
Hematology, indicates that a percentage of schistocytes
greater than 1% of the total red blood cells, in the
absence of other anomalies severe erythrocytes, has
clinical importance for the diagnosis of
microangiopathic hemolytic anemia (35). Although a
percentage of schistocytes greater than 1% can also be
observed in renal failure, hemoglobinopathies, and
neonates, it is usually accompanied by other
erythrocyte morphological changes (36).
One of the most frequent microangiopathic hemolytic
anemias in adults, thrombotic thrombocytopenic
purpura (TTP), has mortality close to 90% in the
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absence of treatment (37). With the introduction of
therapeutic plasma exchange (TPR) in the 1980s,
mortality was reduced to values close to 20% (38-39). Due to
the very high mortality of untreated TTP, TPR is
considered to be indicated as an emergency procedure
in these patients (39).

Blasts
The nding of blasts in peripheral blood, by itself, does
not imply an imminent risk to the life of patients;
however, its identi cation and morphological
description are crucial for making therapeutic decisions,
and a delay in its reporting can can predispose to
potentially serious damage. For this reason, blasts t the
de nition of “vital values”: outcomes that are just as
important as critical values, but for which immediate
corrective action is not required (2). Although there is no
no standardized recommendation for reporting vital
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values, the need to include them as a logical extension
of the critical values system has been recognized (40).
The Classi cation of Hematopoietic and Lymphoid
Tissue Tumors of the World Health Organization (WHO)
establishes a value of 20% of blasts in peripheral blood
or bone marrow to de ne acute leukemia (41). Currently,
however, we know that there is considerable
intraindividual (the subject is compared against
himself/herself at diﬀerent times) and interindividual
(the subject is compared against others) variability for
microscopic examination and manual leukocyte count
(42-43)
. Because of this, a blast count of less than 20% may
be "corrected" in a second reading that shows a
percentage above this threshold. Therefore, even a
percentage of blasts below 20% should be reported in
patients without a history of leukemia, with the
promptness corresponding to a vital value.

Bacteria
Although the Wright stain, used in peripheral blood
smears, is designed to identify leukocytes, red blood
cells, and other cellular elements, it can also show
microorganisms such as bacteria and parasites. The
presence of bacteria in peripheral blood is a factor in
poor prognosis and high mortality in patients with
sepsis (44-45). This is a very unusual nding, so possible
contamination of the sample with bacteria from the
central venous catheter must be ruled out (45).

Hemoparasites
As in the case of blasts, a timely report of hemiparasites
in peripheral blood is crucial for making therapeutic
decisions; likewise, a delay in their identi cation could

lead to serious complications. For example, our
country's timely malaria diagnosis is a public health
priority. The WHO emphasizes the early diagnosis and
treatment of malaria patients to reduce incidence and
mortality rates (46), a task in which clinical laboratories
play a leading role. In this sense, a constant
improvement has been veri ed, between 2012 and
2017, in the performance for the microscopic malaria
diagnosis in the country's specialized laboratories (47). In
this context, Dr. Pedro Legua ( 4 8 ) highlights the
importance of timely malaria diagnosis and stresses the
need to identify Plasmodium falciparum correctly.

Abnormal Promyelocytes
By “abnormal promyelocytes” (Figure 1) we mean
promyeloc ytes with abnormal morphological
characteristics that typically appear in the peripheral
blood and bone marrow of patients with acute
promyelocytic leukemia (APL). The WHO recognizes two
m o r p h o l o gi c a l t y p e s o f A P L : t h e “c l a s s i c ” o r
hypergranular form and the microgranular or
hypogranular variant ( 4 9 6 ) . Additionally, other
morphological types with their characteristics have
been described (50).
Although the morphological presentation of APL is
usually heterogeneous (50), in all cases, it is associated
with a high early mortality rate that approaches 17.5%
(51)
. This high mortality rate is related to the phenomenon
of disseminated intravascular coagulation (DIC), which
conditions events of hemorrhage and thrombosis (52),
with intracranial hemorrhage being the leading cause
of death from ALI (53). Therefore, starting treatment as
soon as possible in patients with suspected ALI is
recommended, even before the diagnosis is con rmed
by molecular or genetic techniques (53).

Figure 1. Anomalous prommyelocytes in peripheral blood. <
(Magni cation: 100x. Coloration: Wright) Microphotographs 1-5: Anomalous prommyelocytes of hypergranular
morphological type. Photomicrograph 3: Hypergranular promyelocyte with multiple Auer bodies in the cytoplasm.
Microphotograph 6: Anomalous promyelocyte of microgranular morphological type or "variant".
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Plasma cells
Plasma cells or plasmocytes (Figure 2) are lymphoid cells
of the B lineage that originate in the bone marrow and
whose function is to secrete antibodies. Although they
constitute part of the normal cell population of the
bone marrow, plasma cells are not usually found in the
peripheral blood of healthy people (54). As we will see, the
nding of plasma cells in peripheral blood is related, in
some patients, to a poor prognosis and high mortality.
In patients with multiple myeloma, the presence of
circulating plasma cells in peripheral blood is associated
with a poor clinical course, poor survival, and an
increase in the International Staging System (55).

Similarly, in patients with multiple myeloma, a
percentage greater than 5% of plasma cells in
peripheral blood is considered a marker of a highly
proliferative disease, low life expectancy, and a
prognosis similar to that of plasma cell leukemia (56). Early
mortality in plasma cell leukemia, although it has
decreased in recent decades, it is still signi cantly
higher than in multiple myeloma (57). This entity is
de ned by a plasma cell count greater than 20% of the
total leukocytes in peripheral blood (58), and it is
considered the most aggressive plasma cell neoplasm
with the worst prognosis (59).

Figure 2. Plasma cells in peripheral blood.
(Magni cation: 100x. Coloration: Wright) Photomicrographs 1-6: Plasma cells with intensely basophilic cytoplasm
with an irregular border, ne cytoplasmic processes, clear perinuclear zone, round or oval nuclei with eccentric
location and closed chromatin. Microphotograph 1: A cytoplasmic inclusion is observed. Photomicrograph
5: Plasma cell with scant cytoplasm that could be mistakenly identi ed as an abnormal lymphocyte.
Microphotograph 6: Binucleation is observed.
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Table 2. Critical values for peripheral blood smears.
PARAMETER

CRITICAL VALUES FOR PERIPHERAL BLOOD SMEARS
VALUES / FINDINGS
INTERPRETATION

Schistocytes

> 1% of total red blood cells>

Blasts

20% of total leukocytes (consider

Bacteria
Hemoparasites

Abnormal
promyelocytes

Risk of death from thrombotic
thrombocytopenic purpura.

reporting lower percentages,
according to clinical-pathological
correlation).

Immediate communication of the nding can
prevent potentially serious damage.

Any amount.
Any number on a peripheral blood
smear.

Very poor prognosis in patients with sepsis.
Immediate communication of the nding can
prevent potentially serious damage.

Predominant cell type, lacking
later stages of granulocytic
maturation (myelocyte,
metamyelocyte, neutrophil).

Risk of death from disseminated intravascular
coagulation (DIC).

Correlation with other ndings in
the blood count and coagulation
pro le.
Plasma cells

> 5% of total leukocytes.

Risk of death in multiple myeloma. A value
above 20% is the diagnostic criteria for plasma
cell leukemia, with an aggressive course and
poor prognosis.

DISCUSSION

like triangles; “helmet cells”, damaged red blood cells

One of the most important considerations for reporting
critical values, in the particular case of the hematology
l a b o r a t o r y, i s t h a t a c o r r e c t a n d t h o r o u g h
morphological review be carried out reasonably. For
proper identi cation of some cellular elements and
abnormal shapes, an experienced observer must
examine peripheral blood smears.

with an “amputated” area recognizable by a rectilinear

For example, regarding thtitleon of schistocytes, the
ICSH establishes that the morphology is variable (35) :
crescent-shaped schistocytes must be distinguished
from sickle cells (sickle cells) based on their size, which in
schistocytes is always smaller than a red blood cell; there
are schistocytes with sharp angles or “spines” that look

border, are considered to be equivalent to schistocytes;
keratocytes, damaged red blood cells that appear to
have a pair of "horns" separated by a concave segment,
are also considered schistoc yte equivalents;
microspherocytes, likewise, should be included in the
schistocyte count, but only in the presence of any of the
previously mentioned forms.
The morphology of the abnormal promyelocytes of the
LPA deserves a separate mention. Both morphological
types mentioned by the WHO, the "typical" or
hypergranular and the "variant" or microgranular, have
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speci c characteristics that diﬀerentiate the abnormal

attached to the issuance of interpretive comments in
laboratory tests; In our country, this responsibility

(49)

promyelocyte from its normal counterpart .

corresponds to the medical specialist in clinical
Hypergranular promyelocytes have a cytoplasm lled

pathology. It is currently recommended that the

with granules that range in color from pink to purple.

laborator y results include a description or

These granules are compactly distributed in the

interpretation of the anomaly, information relevant to

cytoplasm and occasionally join or fuse (coalescence);

the diagnosis, suggestions for further examinations,

they are usually comparatively larger than the granules

and even an opinion related to the treatment (61). Critical

of normal promyelocytes and may be so abundant they

value reporting is considered an integral part of the

cover the nuclear rim, obscuring it. Other times, the

interpretive reporting system, providing the clinician

granules are very ne and look like a "dust cloud" in the
cytoplasm. In many cases, abnormal promyelocytes

with information about life-threatening conditions and
prompting prompt and decisive therapeutic action.

present multiple Auer bodies (rod-shaped, basophilic,
crystalline cytoplasmic inclusions), which may adopt a

CONCLUSIONS

bunch or bouquet distribution. The hypergranular

The reporting of critical values is considered a necessary

promyelocyte nucleus is variable in size and shape,

practice in laboratories and is bene cial in the clinical

although it is usually bilobed or kidney-shaped

(49-50)

.

eld. To have the desired impact, they need to be
reported quickly, interpreted by a trained professional,

Microgranular promyelocytes, in contrast, are

and lead to prompt decision-making. Likewise, it is

characterized by an apparent absence of cytoplasmic

recommended that the critical values of each health

granules and a nucleus that is usually bilobed. Not

establishment be chosen by consensus between

infrequently, however, a small number of abnormal

laboratory professionals and those who work in clinical

promyelocytes with distinguishable granules and

areas.

clustered Auer bodies are also seen in microgranular
APL. Currently, we know that the apparent lack of
granules is due to the fact that they are submicroscopic
in size and cannot be seen by light microscopy (49-50).
Regarding plasma cells, since they are cells that are not
normally observed in peripheral blood, special
attention must be paid to correct morphological
identi cation. The normal plasma cell is oval or circular,
with abundant and intensely basophilic cytoplasm, a
clear perinuclear zone corresponding to the Golgi

In the hematology laboratory, the critical values for
complete blood counts comprise a series of quantitative
parameters that, in most cases, are obtained directly
from the automated hematology analyzer; in some
cases, however, they can be corrected by the laboratory
professional through a microscopic analysis (platelet
count, leukocyte diﬀerential, etc.) or a manual
procedure (microhematocrit by centrifugation, etc.). On
peripheral blood smears, critical values include
abnormal morphologic

ndings that often require

evaluation by experienced professionals.

apparatus, a low nucleus/cytoplasm ratio, and a small,
eccentric nucleus with closed and lumpy chromatin.

The recommendations proposed in this article can serve

Additionally, in conditions such as multiple myeloma,

as a basis for other health establishments to prepare

plasma cells usually present atypical features in size,

their own lists of critical values, considering that each

shape, and cytoplasmic coloration, diﬀerent types of

laboratory service must do so in coordination with the

inclusions, abnormalities in the nuclear border, and

interested clinical areas. Likewise, our

multinucleation (60).

recommendations can be used to expand the lists of
critical values in those services that already have a

On the other hand, more and more importance is
Pág. 704
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